for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biogen Inc

BIIB.OQ

Latest Trade

288.10USD

Change

0.91(+0.32%)

Volume

437,362

Today's Range

287.62

 - 

290.79

52 Week Range

215.81

 - 

343.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Biogen To Acquire Novel Clinical Stage Asset With Application In Alzheimer’S Disease And Parkinson’S Disease From Pfizer Inc.

Jan 13 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN TO ACQUIRE NOVEL CLINICAL STAGE ASSET WITH APPLICATION IN ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE FROM PFIZER INC..BIOGEN INC - BIOGEN TO PAY PFIZER $75 MILLION UPFRONT PLUS POTENTIAL MILESTONES OF UP TO $635 MILLION, AND ROYALTIES.BIOGEN INC - BIOGEN AIMS TO INITIATE PF-05251749 PHASE 1B STUDY IN Q4 2020..BIOGEN - PLANS TO DEVELOP PHASE 1 ASSET FOR TREATMENT OF SUNDOWNING IN ALZHEIMER'S DISEASE, IRREGULAR SLEEP WAKE RHYTHM DISORDER IN PARKINSON'S DISEASE.BIOGEN INC - TRANSACTION WILL BE ACCOUNTED FOR AS AN ASSET ACQUISITION.

Banner Life Sciences Receives Favorable Ruling Against Biogen In Patent Infringement Challenge

Jan 9 (Reuters) - Banner Life Sciences::BANNER LIFE SCIENCES RECEIVES FAVORABLE RULING AGAINST BIOGEN IN PATENT INFRINGEMENT CHALLENGE.BANNER LIFE SCIENCES - COURT RULED BANNER'S BAFIERTAM PRODUCT DOES NOT INFRINGE U.S. PATENT WHICH PROTECTS BIOGEN'S PRODUCT TECFIDERA.BANNER LIFE SCIENCES - COURT'S DECISION PERMITS BANNER TO SEEK FINAL FDA APPROVAL OF BAFIERTAM.

Invitae - Behind The Seizure Program Expands Access To Genetic Testing For Children

Jan 8 (Reuters) - Invitae::INVITAE - BEHIND THE SEIZURE PROGRAM FURTHER EXPANDS ACCESS TO GENETIC TESTING FOR CHILDREN TO SPEED DIAGNOSIS OF GENETIC EPILEPSY.INVITAE - BIOGEN, ENCODED THERAPEUTICS, NEUROGENE, PRAXIS PRECISION MEDICINES AND PTC THERAPEUTICS JOINED BEHIND THE SEIZURE PROGRAM.

Biogen Inc On December 19 Authorized A Program To Repurchase Up To $5.0 Bln Of Co's Common Stock

Dec 19 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN INC - ON DECEMBER 19, COMPANY AUTHORIZED A PROGRAM TO REPURCHASE UP TO $5.0 BILLION OF COMPANY'S COMMON STOCK.BIOGEN INC - DECEMBER 2019 SHARE REPURCHASE PROGRAM DOES NOT HAVE AN EXPIRATION DATE..BIOGEN INC - DEC. SHARE REPURCHASE PROGRAM IS IN ADDITION TO PROGRAM AUTHORIZED IN MARCH 2019.

Catalyst Biosciences Announces Global License And Collaboration Agreement To Develop Pegylated CB 2782 For The Treatment Of Dry Age-Related Macular Degeneration

Dec 19 (Reuters) - Catalyst Biosciences Inc <CBIO.O>::CATALYST BIOSCIENCES ANNOUNCES GLOBAL LICENSE AND COLLABORATION AGREEMENT TO DEVELOP PEGYLATED CB 2782 FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION.CATALYST BIOSCIENCES INC - ENTERED INTO A GLOBAL LICENSE AND COLLABORATION AGREEMENT WITH BIOGEN.CATALYST BIOSCIENCES INC - BIOGEN WILL RECEIVE AN EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP AND COMMERCIALIZE CB 2782-PEG.CATALYST - BIOGEN WILL RECEIVE EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP & COMMERCIALIZE CO'S OTHER ANTI-C3 PROTEASES FOR POTENTIAL TREATMENT OF DRY AMD.CATALYST BIOSCIENCES INC - CATALYST WILL RECEIVE A $15 MILLION UPFRONT PAYMENT AND IS ELIGIBLE TO RECEIVE UP TO $340 MILLION IN MILESTONE PAYMENTS.

Biogen Reports Top-Line Results From Phase 2 Study In Progressive Supranuclear Palsy

Dec 13 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN REPORTS TOP-LINE RESULTS FROM PHASE 2 STUDY IN PROGRESSIVE SUPRANUCLEAR PALSY.BIOGEN INC - PRIMARY ENDPOINT OF PHASE 2 PASSPORT STUDY WAS NOT MET.BIOGEN INC - FURTHER DEVELOPMENT OF GOSURANEMAB IN PROGRESSIVE SUPRANUCLEAR PALSY (PSP) WILL NOT BE PURSUED.BIOGEN - TO CONTINUE ONGOING PHASE 2 TANGO STUDY OF GOSURANEMAB FOR MILD COGNITIVE IMPAIRMENT DUE TO AD , GIVEN DIFFERENCES IN DISEASE PATHOLOGY.BIOGEN INC - PRIMARY ENDPOINT, AS MEASURED BY PSP RATING SCALE (PSPRS) AT WEEK 52, WAS NOT STATISTICALLY SIGNIFICANT.BIOGEN INC - PHASE 2 STUDY IN PROGRESSIVE SUPRANUCLEAR PALSY DID NOT DEMONSTRATE EFFICACY ON KEY CLINICAL SECONDARY ENDPOINTS FROM.

Biogen Announces Positive Phase 2 Study Results For Cutaneous Lupus Erythematosus And Systemic Lupus Erythematosus

Dec 3 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN ANNOUNCES POSITIVE PHASE 2 STUDY RESULTS FOR CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) AND SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).BIOGEN INC - PHASE 2 LILAC STUDY MET ITS PRIMARY ENDPOINTS.BIOGEN - STUDY SHOWED STATISTICALLY SIGNIFICANT REDUCTION OF DISEASE ACTIVITY IN PATIENTS WITH CLE AND SLE WHO RECEIVED BIIB059 COMPARED TO PLACEBO.BIOGEN INC - SAFETY AND TOLERABILITY PROFILE OF BIIB059 SUPPORTS ITS CONTINUED DEVELOPMENT.

FDA Accepts Samsung Bioepis’ BLA For SB8 Bevacizumab Biosimilar Candidate

Nov 19 (Reuters) - Samsung Bioepis::FDA ACCEPTS SAMSUNG BIOEPIS’ BLA FOR SB8 BEVACIZUMAB BIOSIMILAR CANDIDATE.IF APPROVED, SB8 WILL BE COMMERCIALIZED IN U.S. BY MERCK & CO., INC., KENILWORTH, NJ, USA.

Alkermes: Receipt Of $150 Mln Milestone Payment From Biogen Related To FDA Approval Of Vumerity

Nov 12 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES ANNOUNCES RECEIPT OF $150 MILLION MILESTONE PAYMENT FROM BIOGEN RELATED TO FDA APPROVAL OF VUMERITY.ALKERMES PLC - FINANCIAL EXPECTATIONS FOR 2019, PROVIDED ON OCT. 23 REFLECT MILESTONE PAYMENT.

Biogen To Expand Biosimilars Portfolio And Gain Access To Additional Markets Through New Transaction With Samsung Bioepis

Nov 6 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN TO EXPAND BIOSIMILARS PORTFOLIO AND GAIN ACCESS TO ADDITIONAL MARKETS THROUGH NEW TRANSACTION WITH SAMSUNG BIOEPIS.BIOGEN INC - PROPOSED TRANSACTION WITH SAMSUNG BIOEPIS CO., LTD. TO SECURE EXCLUSIVE RIGHTS TO COMMERCIALIZE TWO NEW OPHTHALMOLOGY BIOSIMILARS.BIOGEN INC - TO GAIN EXCLUSIVE COMMERCIALIZATION RIGHTS TO TWO OPHTHALMOLOGY BIOSIMILARS REFERENCING LUCENTIS AND EYLEA IN U.S., CANADA, EUROPE, JAPAN, AUSTRALIA.BIOGEN INC - BIOGEN WILL ACQUIRE EXCLUSIVE COMMERCIALIZATION RIGHTS FOR ITS ANTI-TNF PORTFOLIO IN CHINA.BIOGEN INC - WILL ALSO ACQUIRE AN OPTION TO EXTEND ITS EXISTING COMMERCIAL AGREEMENT WITH SAMSUNG BIOEPIS FOR THIS ANTI-TNF PORTFOLIO IN EUROPE.BIOGEN INC - WILL ALSO ACQUIRE AN OPTION TO EXTEND ITS EXISTING COMMERCIAL AGREEMENT WITH SAMSUNG BIOEPIS FOR THIS ANTI-TNF PORTFOLIO IN EUROPE.BIOGEN INC - UNDER TERMS BIOGEN WILL MAKE A $100 MILLION UPFRONT PAYMENT TO SAMSUNG BIOEPIS.BIOGEN INC - BIOGEN MAY PAY SAMSUNG BIOEPIS UP TO $210 MILLION IN ADDITIONAL DEVELOPMENT, REGULATORY AND SALES-BASED MILESTONES.BIOGEN INC - WILL ALSO OBTAIN AN OPTION TO EXTEND TERM OF ITS CURRENT EUROPEAN COMMERCIAL AGREEMENT FOR ITS THREE ANTI-TNF BIOSIMILARS.BIOGEN - UPON CLOSING EXPECTS TO RECORD CHARGE TO RESEARCH AND DEVELOPMENT EXPENSE OF APPROXIMATELY $65 MILLION RELATED TO $100 MILLION UPFRONT PAYMENT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up